DNA Synthesizer Market is estimated to be valued at USD 6.2 Bn in 2025 and is expected to reach USD 22.51 Bn in 2032, exhibiting a compound annual growth rate (CAGR) of 20.2% from 2025 to 2032.
The key factor of the growth of the DNA synthesizer modern is the rising need for DNA synthesis in reseach, diagnostics and in the area of drug discovery. In 2024, there was a sharp increase in the number of orders for the synthetic DNA products of the company Twist Bioscience. This was due to the advancement of new technologies such as CRISPR as well as the rising need for customized DNA sequences in the Pharmaceutical research and development sector. These synthesizers make it possible to prepare custom DNA molecules that allow the exploring the functions of genes, developing new advanced therapeutic molecules and building modified organisms which are the basic requirements of movable biotechnology.
|
Event |
Description and Impact |
|
US-China Technology Trade Tensions and Export Controls |
|
|
Global mRNA Vaccine Manufacturing Scale-Up Initiatives |
|
|
European Union's Digital Single Market and AI Regulation Framework |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Prescribers in clinical practice prioritize DNA synthesizer technologies based on accuracy, speed, cost-effectiveness, and seamless integration with existing laboratory workflows. In first-line treatments, especially in oncology and genetic disorder diagnostics, high accuracy is critical. For example, prescribers favor the Thermo Fisher Applied Biosystems 3500 Series for HER2 gene amplification testing in breast cancer and Illumina MiSeq systems for cost-effective genetic panel testing like BRCA1/BRCA2 screening.
In second-line treatments, where resistance mutation detection is key, platforms with high sensitivity such as Bio-Rad’s QX200 Droplet Digital PCR systems are preferred, particularly for detecting mutations like EGFR T790M in lung cancer. Infectious disease management also relies on precise DNA synthesis technologies for antiviral resistance testing, guiding alternative treatment options.
For advanced, third-line applications involving complex genomic profiling and rare variant detection, prescribers choose high-throughput sequencers like Illumina NovaSeq 6000 to enable comprehensive tumor profiling and access to experimental therapies.
Early-stage disease screening demands cost-efficient and moderate-throughput platforms such as Ion Torrent PGM, favored for targeted panels in population screening like colorectal cancer detection. Overall, prescribers’ preferences are driven by clinical context, treatment goals, and the need for reliable, scalable DNA synthesizer technologies that support personalized medicine across disease stages.
By product type, the Benchtop DNA Synthesizers segment is anticipated to lead the global DNA synthesizers market, accounting for the largest share of 66.5%. This dominance is driven by the growing demand for accessible, compact, and cost-effective DNA synthesis solutions that can be used directly within research laboratories.
Benchtop synthesizers provide researchers with the flexibility to produce custom DNA sequences on-site, reducing turnaround times and enabling rapid prototyping in fields such as synthetic biology, genomics, and diagnostics. The increasing adoption of benchtop models by academic institutions, biotech companies, and pharmaceutical firms is expected to further bolster segment growth.
The Automated DNA Synthesizers segment, while smaller in market share, is gaining traction due to its ability to produce large-scale, high-throughput DNA sequences with minimal manual intervention. These systems are particularly valuable for industrial applications, large research facilities, and high-demand manufacturing environments. As automation technology continues to advance—improving accuracy, speed, and scalability—this segment is expected to see notable expansion in the coming years.
To learn more about this report, Download Free Sample
North America is expected to dominate the global DNA synthesizer market, accounting for over 33.50% share in 2025. This leadership is primarily driven by the presence of a large number of globally recognized DNA synthesizer manufacturers and the consistently high demand for DNA synthesis services from academic, clinical, and industrial research institutions.
The region’s strong life sciences ecosystem, advanced laboratory infrastructure, and well-funded biotechnology sector have created a favorable environment for adoption of advanced synthesis technologies.
The U.S. remains the largest market in the region, underpinned by extensive pharmaceutical and biotechnology R&D, government-backed genomics projects, and a growing focus on synthetic biology for therapeutic development. Canada follows closely, with rising investments in biotechnology startups and public–private partnerships in genomics research. Together, these countries provide a well-established base for both innovation and commercialization of DNA synthesis equipment and services.
Europe is projected to be the second-largest market, holding over 25.0% share in 2025, supported by a robust research and development ecosystem and high demand from the pharmaceutical, biotechnology, and academic sectors. The region’s strong emphasis on genomics, precision medicine, and advanced molecular diagnostics has driven rapid adoption of DNA synthesizers in both public and private laboratories.
Germany leads the European market, benefiting from a large concentration of biotech clusters and strong government funding for life sciences innovation. The U.K. follows with significant investments in synthetic biology initiatives, while France has emerged as a key player in biopharmaceutical R&D. Collaborative EU projects and cross-border research programs are further fueling demand for advanced synthesis platforms across the region.
Asia Pacific is anticipated to be the fastest-growing regional market, with a CAGR of over 15.0% during 2025–2030. This rapid growth is fueled by the expanding pharmaceutical and biotechnology sectors, increasing adoption of synthetic biology in industrial and medical applications, and the rising number of research institutions across the region.
China dominates the Asia Pacific market, backed by heavy government investment in life sciences, rapidly growing biotech hubs, and strong academic–industry collaborations. Japan maintains a leadership position in advanced R&D capabilities and precision medicine applications, while India is emerging as a cost-effective research and manufacturing hub for DNA synthesis. The region’s competitive pricing environment, coupled with increasing talent availability in genomics research, makes it an attractive growth frontier for global synthesizer manufacturers.
Home to a large number of leading DNA synthesizer manufacturers and a robust life sciences sector, the U.S. drives demand through its pharmaceutical, biotech, and academic research ecosystem. Federal funding for genomics projects and a strong synthetic biology industry further cement its leadership.
Canada’s rising biotechnology investments, research funding, and strong collaborations between universities and industry players have positioned it as a key contributor to North America’s market strength.
Germany’s biotech clusters and substantial public and private R&D investments make it the leading DNA synthesizer market in Europe. The country’s focus on molecular diagnostics and advanced therapeutics fuels high adoption rates.
The U.K.’s leadership in synthetic biology, combined with government-supported innovation programs, drives strong demand for DNA synthesizers in healthcare and industrial biotech applications.
France has a thriving pharmaceutical and biotech sector, with significant investments in genomic medicine and biologics manufacturing, supporting steady growth in DNA synthesizer adoption.
China leads the Asia Pacific market due to aggressive government funding in biotech, establishment of large research parks, and rapid expansion of synthetic biology applications in healthcare and industry.
Japan’s advanced R&D capabilities, strong focus on precision medicine, and well-established biotech industry contribute to its position as a leading DNA synthesizer market in the region.
India’s growing biotech manufacturing base, cost-effective research ecosystem, and expanding genomics research capacity make it a rapidly emerging market for DNA synthesizers.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 6.2 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 20.2% | 2032 Value Projection: | USD 22.51 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Thermo Fisher Scientific, Merck KGaA, Agilent Technologies, Danaher Corporation (Integrated DNA Technologies), GenScript Biotech Corporation, Eurofins Genomics, LGC Limited, BioAutomation Corporation, Bio-Rad Laboratories, Twist Bioscience Corporation, Hamilton Company, New England Biolabs, Nippon Genetics, LGC Biosearch Technologies, DNA Script, Ribbon Biolabs GmbH, and Camena Bioscience |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
The field of genetic research has experienced significant advancements in recent years. DNA synthesizers play a crucial role in this research by enabling the synthesis of custom DNA sequences. The growing demand for DNA synthesis is driven by the need to study genetic variations and gene expression and develop new therapeutic modalities such as gene therapies and personalized medicine.
For instance, on October 2, 2023, EVONETIX LTD, the Company developing semiconductor scale technology to improve access to gene synthesis, announced the introduction of new branding to align with its vision to ‘Redefine possible’ through the development and commercialization of its benchtop semiconductor gene synthesis platform. The rebrand follows a period of significant milestones, including external evaluation of Evonetix’s chip-synthesized DNA.
Synthetic biology is an emerging field that combines biology and engineering principles to design and construct new biological parts, devices, and systems. DNA synthesis is a fundamental technology in synthetic biology, allowing scientists to create custom-designed DNA sequences and engineer biological systems. The rising interest in synthetic biology applications, such as biofuels, biopharmaceuticals, and bio-based materials, is fueling the demand for DNA synthesizers.
Next-generation sequencing technologies have revolutionized genomic research by enabling high-throughput sequencing of DNA. DNA synthesizers are used in library preparation for NGS, where short DNA fragments are synthesized and amplified for sequencing. With the increasing adoption of NGS in various fields, including clinical diagnostics, agriculture, and drug discovery, the demand for DNA synthesizers is on the rise.
Personalized medicine, which involves tailoring medical treatments to an individual's genetic makeup, holds great potential for improving patient outcomes. DNA synthesizers play a crucial role in generating custom DNA sequences for diagnostic tests, targeted therapies, and patient profiling. As personalized medicine gains wider adoption and becomes an integral part of healthcare, the demand for DNA synthesizers is expected to increase.
The development and widespread adoption of CRISPR-Cas9 gene editing technology have revolutionized the field of genetic engineering. DNA synthesizers are essential for generating DNA templates and donor sequences required for CRISPR experiments. With the increasing application of CRISPR technology in research, therapeutics, and agriculture, the demand for DNA synthesizers is likely to grow.
DNA has emerged as a potential data storage medium due to its high density and long-term stability. DNA synthesizers are used to encode digital information into DNA sequences. As the demand for data storage continues to grow exponentially, exploring DNA-based data storage presents a significant opportunity for DNA synthesizer manufacturers.
Gene therapies hold immense promise for treating genetic disorders and certain types of cancers. DNA synthesizers are instrumental in the production of therapeutic DNA constructs and viral vectors used in gene therapy approaches. As gene therapies advance and become more mainstream, there will be an increased need for DNA synthesizers to support their development and manufacturing.
There is a growing need for DNA synthesizers that can perform high-throughput synthesis, allowing researchers to rapidly generate large quantities of custom DNA sequences. High-throughput synthesis enables applications such as library preparation for next-generation sequencing, large-scale gene assembly, and screening of DNA-based libraries for drug discovery. DNA synthesizer manufacturers are focusing on improving synthesis speed and scalability to meet this demand.
There is a trend towards the miniaturization and portability of DNA synthesizers. Compact and portable DNA synthesizers offer advantages such as increased flexibility, on-demand synthesis capabilities, and field-based applications. These portable systems are particularly useful in point-of-care diagnostics, field research, and resource-limited settings where access to a fully equipped laboratory may be limited.
Automation and robotics technologies are being integrated into DNA synthesizers to streamline workflows and enhance efficiency. Automated systems can perform tasks such as reagent dispensing, mixing, and purification, reducing manual labor and minimizing human error. The integration of DNA synthesizers with robotic platforms enables high-throughput synthesis and improves reproducibility, making them ideal for large-scale research and industrial applications.
DNA synthesizers are utilizing advanced synthesis methods to improve the efficiency and accuracy of DNA synthesis. Enzymatic synthesis, which uses enzymes instead of traditional chemical methods, offers benefits such as higher fidelity and the ability to incorporate modified nucleotides. Photochemical synthesis, where light is used to activate nucleotide coupling, enables precise control over the synthesis process. These advanced synthesis methods are gaining traction in the DNA synthesizer market.
*Definition: The DNA synthesizer market refers to the industry involved in the manufacturing and sale of instruments and equipment used for synthesizing DNA molecules. DNA synthesizers enable the automated production of custom DNA sequences, which find applications in various fields such as biotechnology, genetic engineering, drug discovery, diagnostics, and synthetic biology. These synthesizers are designed to accurately assemble nucleotides to create specific DNA sequences, facilitating research and development in molecular biology and genetic manipulation.
Share
Share
About Author
Komal Dighe is a Management Consultant with over 8 years of experience in market research and consulting. She excels in managing and delivering high-quality insights and solutions in Health-tech Consulting reports. Her expertise encompasses conducting both primary and secondary research, effectively addressing client requirements, and excelling in market estimation and forecast. Her comprehensive approach ensures that clients receive thorough and accurate analyses, enabling them to make informed decisions and capitalize on market opportunities.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
Schedule a meeting with report Author
